Acme United's third quarter of 2025 delivered record third-quarter net sales of about $49.1 million, up 2% year over year, driven by a 9% increase in first aid products — now roughly two-thirds of revenue — while Westcott cutting-tool sales remained pressured by retailer cancellation of back-to-school and seasonal promotions in the wake of the large tariffs announced earlier in the year. Gross margin improved to 39.1% from 38.5% as management raised prices modestly, negotiated supplier cost reductions and shifted production to lower-tariff locations, and operating profit rose about 3%. Net income nonetheless fell to $1.9 million ($0.46 per diluted share) from $2.2 million ($0.54) a year earlier, entirely because of a higher effective tax rate of 22% versus just 8% in the prior-year quarter, when Acme booked a large stock-option-related tax benefit. The Company strengthened its balance sheet, cutting net bank debt to $23 million from $27 million, and continued to invest in domestic manufacturing — buying a $6.1 million, 78,000-square-foot Spill Magic plant in Mt. Pleasant, Tennessee (online in Q1 2026) and expanding its Med-Nap facility in Florida while tightening FDA/GMP controls to target U.S. hospital and military markets. Management pointed to stabilizing tariffs, resuming promotional activity, automation of the recurring first aid refill business and a next-generation automatic reorder system as drivers of consistent first aid growth and gradual Westcott recovery into 2026.
Okay. Welcome to the Acme United Corporation third quarter 2025 financial results conference call. At this time, I'd like to turn the call over to Walter Johnsen, Chairman and CEO. Please go ahead, sir.
Good morning.
Good morning.
Welcome to the third quarter 2025 earnings conference call for Acme United Corporation. I am Walter C. Johnsen, Chairman and CEO. With me is Paul Driscoll, our Chief Financial Officer, who will first read a safe harbor statement. Paul?
Paul?
Forward-looking statements in this conference call, including without limitation, statements related to the company's plans, strategies, objectives, expectations, intentions, and adequacy of capital and other resources are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, among others, those arising as a result of a challenging global macroeconomic environment characterized by continued high inflation, high interest rates, and the imposition of new tariffs or changes in existing tariff rates. In addition, we have experienced supply chain disruptions, and we may experience these disruptions in the future. We are also subject to additional risks and uncertainties as described in our periodic filings with the Securities and Exchange Commission and in our current earnings release. Thank you, Paul.
Acme United had net revenues of $49 million in the third quarter of 2025 compared to $48 million in 2024. Our net income was $1.9 million compared to $2.2 million last year. Earnings per share were $0.46 compared to $0.54 in 2024. Our sales in the third quarter increased 2%. Sales of first aid products, which represent about two-thirds of our corporate revenues, increased 9%. We had strong e-commerce sales, consistent demand from our industrial customer base, and solid recurring revenues of refills of components for our first aid kits. However, our sales of our Westcott cutting tools continued to be reduced by the cancellation of back-to-school and retail promotions due to the confusion and uncertainty when large tariffs were announced earlier this year.
As you can imagine, buyers at that time were entirely focused on reducing the impact of the tariff costs and seeking alternative sourcing locations rather than new business. We are seeing stability in the market today with an increase in promotional activity, which we expect in the coming quarters. Our gross margins have also started to stabilize at about 38% to 39%. We increased selling prices modestly to offset tariffs and successfully negotiated cost reductions with our suppliers. We have been shifting production locations to reduce tariffs and increasing our production in the United States. This takes time and is a tremendous amount of effort, but we are making progress. Our operating income grew consistently with revenues during the quarter. As you may remember, we purchased a 78,000-square-foot manufacturing facility on 12 acres with room for expansion in July for $6.1 million.
The new plant will produce our Spill Magic cleanup products for bodily fluids, blood, and spills and comes online in the first quarter of 2026. We have been investing in our MedNap facility in Brooksville, Florida, to increase production of alcohol prep pads, PZK wipes, triple antibiotic packets, and lens wipes. Sales of these domestically produced items are increasing. Concurrently, we have also been expensing the costs of tightening our GMP controls and improving FDA compliance training in preparation for possibly entering the U.S. hospital and military markets in a larger way. As we look into the coming quarters, we see consistent growth in our first aid business and a gradual improvement in Westcott sales. We continue to strengthen our balance sheet and to increase and to generate and review acquisition opportunities. I will now turn the call to Paul.
Corporation's net sales for the third quarter were $49.1 million compared to $48.2 million in 2024, an increase of 2%. Sales for the nine months ended September 30, 2025, were $149 million compared to $148.5 million in the same period in 2024. Net sales in the U.S. segment increased 1% in the third quarter. Sales of first aid and medical products were strong. However, sales of school and office products were lower, mainly due to the cancellation of customer orders as a result of tariff uncertainty. U.S. sales declined 1% for the nine months ended September 30. Net sales in Europe increased 6% in local currency for the quarter, mainly due to higher sales of school and office products into the e-commerce channel. Sales for the nine months decreased 2%.
Net sales in local currency for Canada increased 7% in the quarter and 16% for the year to date, mainly due to higher sales of first aid products. The gross margin was 39.1% in the third quarter of 2025 compared to 38.5% in 2024. The gross margin was 39.8% for the first nine months of 2025 compared to 39.4% in 2024. SG&A expenses for the third quarter of 2025 were $16.2 million, or 33% of sales, compared with $15.6 million, or 33% of sales for the same period of 2024. SG&A expenses for the first nine months of 2025 were $47 million, or 32% of sales, compared with $47 million, or 31% of sales in 2024. Operating profit in the third quarter of 2025 increased 3% compared to the third quarter in 2024.
Net income for the third quarter of 2025 was $1.9 million, or $0.46 per diluted share, compared to a net income of $2.2 million, or $0.54 per diluted share for the same period of 2024, a decrease of 14% in net income and 15% in earnings per share. Despite the increase in operating profit, net income in the quarter declined due to higher tax expense. In the third quarter of 2024, we recorded a large tax benefit related to the exercising of stock options. This resulted in an effective tax rate of 8% in last year's third quarter compared to 22% this year. Net income for the first nine months ended September 30, 2025, and 2024 was $8.3 million, or $2.03 per diluted share. The company's bank debt, less cash, on September 30, 2025, was $23 million compared to $27 million on September 30, 2024.
During the 12-month period, we paid $2.3 million in dividends and generated $11 million in free cash flow before the $6 million purchase of our new facility in Tennessee.
Thank you, Paul. I will now open the call to questions.